Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
European Journal of Cancer · 2025-07 · 225 · 115534
DOI: 10.1016/j.ejca.2025.115534 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025-07. Verfasst von H Blons und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institut du Cancer Paris Carpem, APHP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hopital Européen Georges Pompidou, Paris,…. Hauptthemen laut MEDLINE: DNA Methylation, Ovarian Neoplasms, BRCA1 Protein, DNA-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: ARC Foundation for Cancer Research.
Abstract (Originalsprache)
IMPORTANCE AND BACKGROUND: In high-grade serous ovarian cancer (HGSOC) bevacizumab (bev)/olaparib (ola) maintenance was approved for patients with homologous recombination DNA repair deficiency (HRD+) tumors. Although different methods exist to score genomic instability, DNA quality, tumor cell content, and costs may impair our ability to identify patients that will benefit from treatment. PATIENTS AND METHOD: We analyzed BRCA1 and RAD51C methylation as an HRD determination tool in patients newly diagnosed of HGSOC (n = 519) based on data from the PAOLA-1/ENGOT-ov25 trial phase III prospective trial. Methylation was analyzed using quantitative methylation specific PCR, correlated to HRD scores, PFS and OS. RESULTS: 67 (12.9 %) were BRCA1 and 25 (4.8 %) were RAD51C methylated. Of the 81 samples with a failed HRD score, 13 were methylated. Methylated samples were HRD+ (mean score [95 % CI]; 65.9 [62.7-69.1] and 53.3 [48.0-58.6]) and almost mutually exclusive of BRCA1&2 mutations. A significant PFS1 benefit independently of methylation ratios was observed in patients with methylated tumors with bev-ola maintenance compared to bev alone (HR=0.49, 95 % CI 0.29-0.83, P = 0.008). An OS benefit was shown for patients defined as "all-HRD" (including methylation) (HR=0.59, 95 % CI 0.41-0.86, P = 0.007). CONCLUSIONS: This study confirms the feasibility and clinical value of BRCA1/RAD51C methylation for predicting response to ola-bev maintenance in newly diagnosed HGSOC. Assessment of methylation in parallel to mutation testing allowed the identification of nearly 85 % of HRD+ samples at low costs. This study suggests that methylation testing could be easily implemented to optimize the selection of patients that benefit from olaparib+bevacizumab maintenance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut du Cancer Paris Carpem, APHP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hopital Européen Georges Pompidou, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Fran…
- Centre de Recherche des Cordeliers, Sorbonne Université, France; Université Paris Cité, Inserm Paris, France.
- Institut du Cancer Paris Carpem, APHP, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hopital Européen Georges Pompidou, Paris, France.
- Centre de Recherche des Cordeliers, Sorbonne Université, France; Université Paris Cité, Inserm Paris, France; Institut du Cancer Paris Carpem, APHP, Department of Genomics medicine of tumors and cancers, Hopital Europée…
- Medical oncology, Hospices Civils de lyon (HCL), CITOHL, EPSILYON, EA 3738, CICLY, Lyon, France.
- Department of Gynecology & Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; AGO, Germany.
Förderung
- ARC Foundation for Cancer Research
Zitieren
APA
Blons, H., Abdelli, J., Landman, S., Taly, V., Mulot, C., Laurent-Puig, P., You, B., Harter, P., Lorusso, D., García-García, Y., Polterauer, S., Hietanen, S., Colombo, N., Vergote, I., Kobayashi, H., De La Motte Rouge, T., Buderath, P., Cecere, S. C., Bataillon, G., …, & Ray-Coquard, I. (2025). Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. European Journal of Cancer, 225, 115534. https://doi.org/10.1016/j.ejca.2025.115534
Vancouver
Blons H, Abdelli J, Landman S, Taly V, Mulot C, Laurent-Puig P, et al. Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. European Journal of Cancer. 2025;225:115534. doi:10.1016/j.ejca.2025.115534
BibTeX
@article{Blons2025,
author = {Blons, H and Abdelli, J and Landman, S and Taly, V and Mulot, C and Laurent-Puig, P and You, B and Harter, P and Lorusso, D and García-García, Y and Polterauer, S and Hietanen, S and Colombo, N and Vergote, I and Kobayashi, H and De La Motte Rouge, T and Buderath, P and Cecere, S C and Bataillon, G and Pujade-Lauraine, E and Ray-Coquard, I},
title = {Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial},
journal = {European Journal of Cancer},
year = {2025},
volume = {225},
pages = {115534},
doi = {10.1016/j.ejca.2025.115534}
}
EUVIMED